Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 11:20:44 Source:entertainmentViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
You may also like
- Concussion replacements added for Copa America under the pink substitution pass system
- Families of Mexican farmworker bus crash victims mourn the loss of their loved ones
- Workers at 2 Mercedes plants in Alabama are voting against joining a union early in the vote count
- Georgia Harrison puts on a sizzling display in a skimpy cheetah
- How major US stock indexes fared Monday, 5/20/2024
- Bike shops boomed early in the pandemic. It’s been a bumpy ride for most ever since
- Marseille coach Gasset, 70, says he will retire at the end of the season
- San Diego FC partners with Club Tijuana for a series of matches
- Election 2024: Biden and the Democrats raised far less in April than Trump and the GOP